SOLASTA Bio candidates are aimed at the €18B global insecticides market and will be licenced to Agrochemical ...
SOLASTA Bio candidates are aimed at the €18B global insecticides market and will be licenced to Agrochemical Corporates (Ag Corp), who are best placed to complete large-scale field trials and have global sales channels.
The company is incubated at University of Glasgow, with excellent laboratory space, and facilities for genome analysis, fast screening, insect rearing and testing facilities.
SOLASTA Bio’s IWT platform, portfolio of lead biopesticides and the founding team are the core assets of the business. The company’s strategy is to focus on developing the existing lead products against key insect pests to greenhouse/ small field proof of concept studies. This data package will be used to secure agreements with Ag Corp with a view to entering co-development and licensing deals, providing upfront payments, milestones and product royalties.
The IWT platform represents a profound change for how insect control agents are discovered, being rooted in insect physiology rather than traditional synthetic chemistry. This provides the company with a disruptive competitive advantage, balancing risk with high reward. Achieving deals with Ag Corp will validate the IWT platform and the company’s business model sufficiently to secure a major Series A investment from VC’s that will enable SOLASTA Bio to expand and develop its operations. This will signpost IWT platform potential to the global AG industry modern biopesticides that meet grower and consumer demands.
I worked with Solasta on a due diligence : Super team, they were real experts on the product and its application ! Plus, it is a very useful innovation that can be game changing in environment protection.